| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T329 |
0-15 |
Sentence |
denotes |
• COV-AID Trial |
| T330 |
16-93 |
Sentence |
denotes |
• Use of anti-interleukin agents for cytokine storm • Phase 3 prospective RCT |
| T331 |
94-133 |
Sentence |
denotes |
• Patients with signs of cytokine storm |
| T332 |
134-178 |
Sentence |
denotes |
• N = 38 Anakinra alone (anti-IL-1 receptor) |
| T333 |
179-217 |
Sentence |
denotes |
• N = 76 Siltuximab alone (anti-IL-6) |
| T334 |
218-249 |
Sentence |
denotes |
• N = 38 Anakinra + siltuximab |
| T335 |
250-297 |
Sentence |
denotes |
• N = 76 Tocilizumab alone (anti-IL-6 receptor) |
| T336 |
298-329 |
Sentence |
denotes |
• N = 38 Anakinra + tocilizumab |
| T337 |
330-358 |
Sentence |
denotes |
• N = 76 standard care alone |
| T338 |
359-449 |
Sentence |
denotes |
• Primary outcome as time to clinical improvement • Anakinra 100 mg s.c. daily for 28 days |
| T339 |
450-492 |
Sentence |
denotes |
• Siltuximab single i.v. infusion 11 mg/kg |
| T340 |
493-566 |
Sentence |
denotes |
• Tocilizumab single i.v. infusion 8 mg/kg max 800 mg (Maes et al., 2020) |
